Symposium Sessions
Introduction to the Programme
Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada
CHAIR: Ranjit Manchanda, MD, MRCOG, PhD, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
9:15 - 9:35
LECTURE
Testing the limits of population-based testing
Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
9:35 - 9:55
LECTURE
Population testing for HBOC genes: time for action
Funmi Olopade, MD, FACP, OON, Center for Clinical Cancer Genetics, University of Chicago Medicine, Chicago, IL, USA
9:55 - 10:05
PROFFERED PAPER 1 (S9-PP1)
Hereditary cancer testing In an unselected 'Healthy' Canadian population: Is it time to consider population screening?
Jessica Gu, MSc, MS, Medcan, Toronto, ON, Canada
10:05 - 10:15
PROFFERED PAPER 2 (S9-PP2)
Implementation and outcomes of a program to increase hereditary cancer testing ordered by genetics and non-genetics providers in over 12,500 patients
Monica Alvarado, MS, LCGC, Kaiser Permanente Southern California, Pasadena, CA, United States
10:17 - 10:20
RAPID FIRE POSTER PRESENTATIONS (S9-RF1)
Genetic contribution of BRCA1 in hereditary breast and ovarian cancer in Senegalese women
Rokhaya Ndiaye, PhD, University Cheikh Anta Diop, Dakar, Senegal
10:20 - 10:23
RAPID FIRE POSTER PRESENTATIONS (S9-RF2)
Early insights from the DNA screen study, an Australian pilot study of population genomic screening
Tu Nguyen-Dumont, PhD, Monash University, Clayton, VIC, Australia
10:25 - 10:45
Question and discussion period (all speakers)
Moderated 90-minute interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of one of the following 2 SIGs.
SIG 7:
Alternative Models of Service Delivery
In this session, the presenters will explore alternative models of cancer genetics service delivery that have arisen in response to expanding indications for genetic testing, increasing demand for hereditary cancer services and the need to dramatically improve cascade genetic testing rates. Attendees will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.
Intan Schrader, MBBS, PhD, BC Cancer, Vancouver, BC, Canada (session lead)
Kelly Metcalfe, RN, PhD, Women's College Research Institute, University of Toronto, On, Canada
Nicoline Hoogerbrugge, MD, PhD, Radboud University Medical Center, Nijmegen, The Netherlands
SIG 8:
The lower risk and rarer breast and/or ovarian cancer genes – What do we know and what should we do with what we know? (e.g. CHEK2, ATM, BRIP1, BARD1, NTHL1)
Presenters will provide a brief update about risk estimates in lower risk breast and ovarian cancer genes, and management based on available practice guidelines. They will review risks of contralateral breast cancer (where available), discuss causation versus coincidence when these genes are identified, gaps in literature, and future directions. Attendees will be encouraged to send in specific cases in advance for discussion at the SIG.
-
Tuya Pal, MD, Vanderbilt – Ingram Cancer Center, Nashville, TN, USA (session lead)
Raymond Kim, MD, PhD, Princess Margaret Cancer Centre, Toronto, ON, Canada
Helen Hanson, MBBS, MD(Res), St George's Hospital, London, UK
Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK
Introductory Remarks
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada
LECTURE
Optimizing Treatment of Breast Cancer in BRCA1 Carriers
Steven Narod, MD, PhD, Senior Scientist, Women’s College Hospital, Toronto, ON, Canada
Presentation by the Miller Family
Closing Remarks
Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada
